Early-access Avacopan in Real-world ANCA-associated Vasculitis

Launched by LEIDEN UNIVERSITY MEDICAL CENTER · Jan 22, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at the use of a medication called avacopan for patients with ANCA-associated vasculitis, a condition that affects the blood vessels and can harm different organs in the body. The researchers want to understand how avacopan is being used in real-world settings across Europe, particularly focusing on how patients respond to this treatment and the characteristics of those who receive it. By gathering this information, the study aims to improve the way avacopan is used and potentially fill in gaps in our understanding of this medication.

To be part of this trial, participants need to have been diagnosed with either Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA) and should be starting treatment with avacopan. The study is open to adults aged 16 and older. Participants will be asked to provide consent for their medical data to be used in the research, and they can expect to share their experiences and outcomes while being treated with avacopan. This trial is currently recruiting participants and hopes to gather valuable insights that could help improve treatment for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Established diagnosis of GPA or MPA
• • Treatment (initiation) with avacopan
• • Informed consent for use of medical data
• Exclusion Criteria:
• • If there is no AAV disease activity present that can be supported by an objectifiable clinical measure or assessment
• • If a subject is below 16 years old